Cart (0 Items)
Your cart is currently empty.
View ProductsSize | 100ug |
---|---|
Brand | Arovia |
Product type | Recombinant Proteins |
Product name | Recombinant DENV-1 Envelope protein E, N-His |
---|---|
Origin species | Dengue virus type 1 (strain Nauru/West Pac/1974) (DENV-1) |
Expression system | Prokaryotic expression |
Molecular weight | 13.40 kDa |
Buffer | 0.01M PBS, pH 7.4. |
Form | Liquid |
Delivery condition | Dry Ice |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
Brand | Arovia |
Host species | Escherichia coli (E.coli) |
Fragment Type | Met577-Lys680 |
Aliases /Synonyms | Genome polyprotein, Capsid protein C, Core protein, Protein prM, Peptide pr, Small envelope protein M, Matrix protein, Envelope protein E, Non-structural protein 1, NS1, Non-structural protein 2A, NS2A, Serine protease subunit NS2B, Flavivirin protease NS2B regulatory subunit, Non-structural protein 2B, Serine protease NS3, 3.4.21.91, 3.6.1.15, 3.6.4.13, Flavivirin protease NS3 catalytic subunit, Non-structural protein 3, Non-structural protein 4A, NS4A, Peptide 2k, Non-structural protein 4B, NS4B, RNA-directed RNA polymerase NS5, 2.1.1.56, 2.1.1.57, 2.7.7.48, Non-structural protein 5, Dengue Virus (DENV) |
Reference | ARO-P12712 |
Note | For research use only. |
Recombinant DENV-1 Envelope protein E (rDENV-1 E) is a genetically engineered protein that is derived from the envelope protein of the Dengue virus serotype 1 (DENV-1). This protein is a crucial component of the virus and plays a vital role in its structure, activity and pathogenesis. In recent years, rDENV-1 E has gained significant attention in the scientific community due to its potential as a diagnostic tool and vaccine candidate for Dengue virus.
The rDENV-1 E protein is composed of 496 amino acids and has a molecular weight of approximately 55 kDa. It is a type I transmembrane protein, with a signal peptide at the N-terminus and a transmembrane domain at the C-terminus. The protein consists of three distinct domains – domain I, II and III. Domain I is the central domain and is responsible for the dimerization of the protein. Domain II is the fusion loop domain, which is involved in the fusion of the virus with host cells. Domain III is the receptor-binding domain, which is responsible for the attachment of the virus to host cells.
The rDENV-1 E protein is an essential component of the Dengue virus and is involved in multiple stages of the virus life cycle. It plays a crucial role in the attachment and entry of the virus into host cells. The fusion loop domain of rDENV-1 E interacts with host cell receptors, leading to the internalization of the virus. Additionally, rDENV-1 E is also involved in the assembly and release of new viral particles from infected cells.
Apart from its role in the virus life cycle, rDENV-1 E also has immunogenic properties. It can induce a strong immune response in the host, leading to the production of neutralizing antibodies. These antibodies can bind to the virus and prevent its entry into host cells, thereby providing protection against infection.
The unique structural and functional properties of rDENV-1 E make it a promising candidate for various applications in the field of Dengue virus research. One of the major applications of rDENV-1 E is in the development of diagnostic tools for Dengue virus infection. The protein can be used as an antigen in serological tests, such as ELISA, to detect the presence of antibodies against the virus in patient samples. This can aid in the early and accurate diagnosis of Dengue virus infection.
Moreover, rDENV-1 E is also being investigated as a potential vaccine candidate for Dengue virus. The protein has been shown to induce a strong immune response in animal studies, making it a promising candidate for the development of a safe and effective vaccine against Dengue virus. Additionally, rDENV-1 E can also be used in the development of therapeutic antibodies for the treatment of Dengue virus infection.
In conclusion, rDENV-1 E is a genetically engineered protein derived from the envelope protein of the Dengue virus serotype 1. It plays a crucial role in the structure, activity and pathogenesis of the virus. The protein has potential applications in the development of diagnostic tools and vaccines for Dengue virus. Further research and development of rDENV-1 E can lead to significant advancements in the prevention and treatment of Dengue virus infection.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.